abrdn Life Sciences Investors
HQL
49 hedge funds and large institutions have $43.4M invested in abrdn Life Sciences Investors in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 6 closing their positions.
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
1.02% less ownership
Funds ownership: 13.53% → 12.51% (-1%)
6% less funds holding
Funds holding: 52 → 49 (-3)
30% less capital invested
Capital invested by funds: $61.8M → $43.4M (-$18.3M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
Doliver Advisors
Houston,
Texas
|
+$971K |
| 2 |
Citigroup
New York
|
+$817K |
| 3 |
Morgan Stanley
New York
|
+$527K |
| 4 |
NIM
Needham Investment Management
New York
|
+$261K |
| 5 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$197K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Advisors Asset Management
Monument,
Colorado
|
-$2.14M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.23M |
| 3 |
UR
USCA RIA
Houston,
Texas
|
-$848K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$778K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$651K |
HQL Hedge Fund Activity: Q1 2016 in Review
49 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q1 2016, worth a combined $43.4M — down 30% from $61.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of HQL and 3 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 17 added.
The largest buyer was Doliver Advisors, adding an estimated $971K. The largest seller was Advisors Asset Management, cutting an estimated $2.14M.
- 49 institutional investors held abrdn Life Sciences Investors (HQL) as of Q1 2016, down from 52 in Q4 2015.
- Funds reported $43.4M of abrdn Life Sciences Investors stock for Q1 2016, down 30% quarter-over-quarter.
- 3 funds opened new abrdn Life Sciences Investors positions in Q1 2016 and 6 closed out, a net change of -3 holders.
- The largest abrdn Life Sciences Investors buyer in Q1 2016 was Doliver Advisors, an estimated $971K added.
- The largest abrdn Life Sciences Investors seller in Q1 2016 was Advisors Asset Management, an estimated $2.14M sold.
Based on aggregated 13F filings for Q1 2016.